Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Jaguar Gene Therapy.

    Client Virtual Booth

    JAGUAR GENE THERAPY

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Jaguar Gene Therapy
    Israel Flag
    Country
    Country
    Israel
    Address
    Address
    Lake Forest, IL
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://jaguargenetherapy.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Jaguar Gene Therapy Announces FDA Clearance of IND to Study JAG201 in a Genetic Form of Autism Spectrum Disorder and Phelan-McDermid Syndrome

    Details:

    JAG201 is being evaluated in preclinical studies for the treatment of SHANK-3 mutated autism spectrum disorder & Phelan-McDermid syndrome. It aims to deliver functional SHANK3 via the AAV9 vector to treat the root cause of the disease.


    Lead Product(s): JAG201

    Therapeutic Area: Genetic Disease Product Name: JAG201

    Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 31, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Jaguar Gene Therapy Presents Preclinical Data of JAG101 in Type 1 Galactosemia at American Society of Gene and Cell Therapy 25th Annual Meeting

    Details:

    Preclinical studies support continued development of JAG101, an investigational gene therapy designed to address the root cause of Type 1 galactosemia and reduce multiple toxic metabolites.


    Lead Product(s): JAG101

    Therapeutic Area: Genetic Disease Product Name: JAG101

    Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 16, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Jaguar Gene Therapy Closes $139 Million Series B Funding Co-Led by Eli Lilly and Company and Deerfield Management

    Details:

    Jaguar will use Series B funding proceeds to continue to advance its initial pre-clinical pipeline, which utilizes the proven and well-characterized AAV9 vector to target diseases in larger patient populations with significant unmet need.


    Lead Product(s): JAG101

    Therapeutic Area: Genetic Disease Product Name: JAG101

    Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Eli Lilly

    Deal Size: $139.0 million Upfront Cash: Undisclosed

    Deal Type: Series B Financing April 13, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Jaguar Gene Therapy Launches with Mission to Accelerate Breakthroughs in Gene Therapy for Patients Suffering from Severe Genetic Diseases

    Details:

    Jaguar Gene Therapy is focused on advancing its initial pre-clinical pipeline of AAV9-based gene therapies which includes JAG101, JAG201, JAG301, AXV101 focusing on key therapeutic areas such as galactosemia, autism spectrum disorder, Type 1 diabetes and BBS1 respectively.


    Lead Product(s): JAG101

    Therapeutic Area: Genetic Disease Product Name: JAG101

    Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 25, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search